CHICAGO—Sunitinib (Sutent) remains a reference standard for the first-line treatment of metastatic renal cell carcinoma (RCC), with updated findings from a phase 3 trial confirming the superior efficacy of this agent over interferon-alfa, researchers reported here at the American Society of Clinical Oncology annual meeting.

CHICAGO—Everolimus, an experimental targeted therapy, significantly delays progression of metastatic kidney cancer in patients whose disease has worsened despite treatment, according to results of a phase III trial.

WASHINGTON, D.C.—Cryoablation is an appropriate option for patients with unresectable renal masses, but long-term follow-up studies are needed before this modality can be expanded to treatment of all potential surgical candidates, researchers say.

SAN DIEGO—Dutch researchers say that they have identified potential biomarkers which might help physicians monitor the effectiveness of bevacizumab in non-small-cell lung cancer (NSCLC) patients and in patients with advanced kidney cancer treated with sunitinib.

WASHINGTON, D.C.—A "halo sign" is a common delayed finding following radiofrequency ablation (RFA) of kidney tumors, according to researchers at the University of Toronto.

DIETARY INTAKE of acrylamide, a probable human carcinogen, may be associated with an increased risk of renal cell cancer, according to a report in the American Journal of Clinical Nutrition (2008;87:1428-1438).

DIETARY INTAKE of acrylamide, a probable human carcinogen, may be associated with an increased risk of renal cell cancer, according to a report in the American Journal of Clinical Nutrition (2008;87:1428-1438).

SAN FRANCISCO—Researchers are concerned about cardiotoxicity associated with sunitinib, a treatment for advanced kidney cancer.

WASHINGTON D.C—CT-guided percutaneous cryoablation of renal tumors appears to be a viable option for the treatment of selected small renal cell tumors, according to new data presented at the 2008 Society of Interventional Radiology 33rd Annual Scientific Meeting.

WASHINGTON, D.C.—Most, if not all, complications from CT-guided percutaneous cryoablation for renal cell carcinoma (RCC) are either preventable or reversible, investigators say.